Seeing Is Believing
Currently out of the existing stock ratings of Li Watsek, 77 are a BUY (95.06%), 4 are a HOLD (4.94%).
Analyst Li Watsek, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 27.45% that have a potential upside of 50.49% achieved within 116 days.
Li Watsek’s has documented 141 price targets and ratings displayed on 17 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ASND, Ascendis Pharma AS at 15-Nov-2024.
Analyst best performing recommendations are on FATE (FATE THERAPEUTICS).
The best stock recommendation documented was for CRVS (CORVUS PHARMACEUTICALS) at 8/3/2021. The price target of $5 was fulfilled within 45 days with a profit of $2.9 (138.1%) receiving and performance score of 30.69.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$21
$12.81 (156.41%)
$12
2 months 5 days ago
(16-Sep-2024)
1/4 (25%)
$15.22 (263.32%)
216
Buy
$4
7 months 20 days ago
(01-Apr-2024)
3/4 (75%)
$2.36 (143.90%)
376
Hold
$3.5
$-4.69 (-57.26%)
$3.5
1 years 5 months 5 days ago
(16-Jun-2023)
6/7 (85.71%)
$1.26 (56.25%)
321
Buy
$8
$6.54 (447.95%)
2 years 11 months 19 days ago
(02-Dec-2021)
0/1 (0%)
$4.69 (141.69%)
Buy
$5
4 years 1 months 16 days ago
(05-Oct-2020)
2/4 (50%)
$2.85 (132.56%)
313
Which stock is Li Watsek is most bullish on?
Which stock is Li Watsek is most reserved on?
What Year was the first public recommendation made by Li Watsek?